TY - EJOU AU - TORIZAL, FUAD GANDHI AU - KERANS, FRANSISCUS FIANO ANTHONY AU - KHUMAIRA, ANNISA TI - Production of mesenchymal stem cell derived-secretome as cell-free regenerative therapy and immunomodulation: A biomanufacturing perspective T2 - BIOCELL PY - 2022 VL - 46 IS - 8 SN - 1667-5746 AB - The potential of mesenchymal stem cells (MSCs) in regenerative medicine has been largely known due to their capability to induce tissue regeneration in vivo with minimum inflammation during implantation. This adult stem cell type exhibit unique features of tissue repair mechanism and immune modulation mediated by their secreted factors, called secretome. Recently, the utilization of secretome as a therapeutic agent provided new insight into cell-free therapy. Nevertheless, a sufficient amount of secretome is necessary to realize their applications for translational medicine which required a proper biomanufacturing process. Several factors related to their production need to be considered to produce a clinical-grade secretome as a biological therapeutic agent. This viewpoint highlights the current challenges and considerations during the biomanufacturing process of MSCs secretome. KW - Secretome KW - MSCs KW - Culture system DO - 10.32604/biocell.2022.019591